A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

2024-514034-20-00 Protocol 1443-0003 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 16 Nov 2021 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol 1443-0003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 13
Countries 1
Sites 1

non-small cell lung cancer or

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
16 Nov 2021 → ongoing
Decision date (initial)
2024-07-29
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-514034-20-00
EudraCT number
2021-001063-25

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

non-small cell lung cancer or

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruitment ended 13 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruitment ended
Stichting Amsterdam UMC
Radiology & Nuclear Medicine, De Boelelaan 1117, 1081 HV, Amsterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2021-11-16 2022-03-03 2026-01-07

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-15 Netherlands Acceptable with conditions
2024-07-29
2024-07-29
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-10-29 Netherlands Acceptable with conditions
2024-07-29
2024-10-29
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-03-14 Netherlands Acceptable with conditions
2024-07-29
2025-03-14
4 NON SUBSTANTIAL MODIFICATION NSM-3 2025-08-06 Netherlands Acceptable with conditions
2024-07-29
2025-08-06